You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Complementary medicines filter Complementary medicines (7)
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (3)
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Advertising filter Advertising
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Other therapeutic goods filter Other therapeutic goods
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018
Options for the future regulation of 'low risk' products
Closed on 12 May 2017
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012